{
    "data": [
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1R3:0",
            "title": "UnitedHealth caps employee pay raises to 2%, Bloomberg News reports",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>    UnitedHealth Group </span><span> has limited employee pay raises this year to between 0% and 2%, depending on performance, Bloomberg News reported on Friday, citing a person familiar with the matter.</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The modest compensation increases come as the company recently told an unspecified number of workers they were being laid off, Bloomberg reported, citing the person.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>UnitedHealth did not immediately respond to a Reuters request for comment.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company earlier this year         said         2026 revenue would decline for the first time in decades.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company's shares were also pressured after the Trump administration proposed a much smaller-than-expected increase to 2027 Medicare Advantage rates.      </span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1R3:0-unitedhealth-caps-employee-pay-raises-to-2-bloomberg-news-reports/",
            "pub_date": "2026-02-28 02:06:54",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008729:0",
            "title": "Ingevity Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:07 GMT) </span></strong><span>Ingevity Price Target Raised to $75.00/Share From $65.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008729:0/",
            "pub_date": "2026-02-28 02:07:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008731:0",
            "title": "Ardagh Metal Packaging Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:07 GMT) </span></strong><span>Ardagh Metal Packaging Price Target Raised to $5.00/Share From $4.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008731:0/",
            "pub_date": "2026-02-28 02:07:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1S7:0",
            "title": "Measles cases in South Carolina rise by 6 to 985",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Measles cases in South Carolina surged to 985 on Friday, state health data showed, including six additional infections since Tuesday.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1S7:0-measles-cases-in-south-carolina-rise-by-6-to-985/",
            "pub_date": "2026-02-28 02:07:06",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008740:0",
            "title": "Kinder Morgan Is Maintained at Sector Perform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008740:0/",
            "pub_date": "2026-02-28 02:08:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008738:0",
            "title": "Cable One Is Maintained at Underweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008738:0/",
            "pub_date": "2026-02-28 02:08:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8036Ua:0",
            "title": "REG - FTSE Russell - 3 3/4% Treasury Gilt 2027",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8036U  FTSE Russell  27 February 2026   </span><p class=\"\"><span>Shortener: 3 3/4% Treasury Gilt 2027</span></p><p class=\"\"><span> Changes to FTSE Indices</span></p><p class=\"\"><span>27 February 2026</span></p><p class=\"\"></p><p class=\"\"><span>With the imminent shortening of maturity of 3 3/4% Treasury Gilt 2027 (BPSNB46, GB00BPSNB460), please see details of affected indices and effective dates below:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Index</span></p></td><td><p class=\"\"><span>FTSE Actuaries UK Conventional Gilts Yield Indices</span></p></td></tr><tr><td><p class=\"\"><span>Change</span></p></td><td><p class=\"\"><span>3 3/4% Treasury Gilt 2027 (BPSNB46, GB00BPSNB460) will be deleted from the index.</span></p></td></tr><tr><td><p class=\"\"><span>Effective From</span></p><p class=\"\"><span>Start of Trading</span></p></td><td><p class=\"\"><span>06 March 2026</span></p></td></tr></tbody></table></div><p class=\"\"></p><p class=\"\"><span>For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Australia</span></p></td><td><p class=\"\"><span>+61 (0) 2 7228 5659</span></p></td></tr><tr><td><p class=\"\"><span>Hong Kong</span></p></td><td><p class=\"\"><span>+852 2164 3333</span></p></td></tr><tr><td><p class=\"\"><span>Japan</span></p></td><td><p class=\"\"><span>+81 3 6441 1430</span></p></td></tr><tr><td><p class=\"\"><span>London</span></p></td><td><p class=\"\"><span>+44 (0) 20 7866 1810</span></p></td></tr><tr><td><p class=\"\"><span>New York</span></p></td><td><p class=\"\"><span>+1877 503 6437</span></p></td></tr></tbody></table></div><p class=\"\"><span>Alternatively, please visit our website at lseg.com/ftse-russell</span></p><p class=\"\"><span> Terms of Use | Copyright © 2026 FTSE Russell</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  FTSGZGZZRNVGVZM</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8036Ua:0-reg-ftse-russell-3-3-4-treasury-gilt-2027/",
            "pub_date": "2026-02-28 02:08:48",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8035Ua:0",
            "title": "REG - FRP Advisory Grp PLC - Holding(s) in Company",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8035U  FRP Advisory Group PLC  27 February 2026   </span><p class=\"\"><span>TR-1: Standard form for notification of major holdings</span></p><p class=\"\"><span>1. Issuer Details</span></p><p class=\"\"><span>ISIN</span></p><p class=\"\"><span>GB00BL9BW044</span></p><p class=\"\"><span>Issuer Name</span></p><p class=\"\"><span>FRP ADVISORY GROUP PLC</span></p><p class=\"\"><span>UK or Non-UK Issuer</span></p><p class=\"\"><span>UK</span></p><p class=\"\"><span>2. Reason for Notification</span></p><p class=\"\"><span>An acquisition or disposal of voting rights</span></p><p class=\"\"><span>3. Details of person subject to the notification obligation</span></p><p class=\"\"><span>Name</span></p><p class=\"\"><span>Raymond James Wealth Management Limited</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>London</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>United Kingdom</span></p><p class=\"\"><span>4. Details of the shareholder</span></p><p class=\"\"><span>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>5. Date on which the threshold was crossed or reached</span></p><p class=\"\"><span>23-Feb-2026</span></p><p class=\"\"><span>6. Date on which Issuer notified</span></p><p class=\"\"><span>24-Feb-2026</span></p><p class=\"\"><span>7. Total positions of person(s) subject to the notification obligation</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td></td><td><p class=\"\"><span>% of voting rights attached to shares (total of 8.A)</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</span></p></td><td><p class=\"\"><span>Total of both in % (8.A + 8.B)</span></p></td><td><p class=\"\"><span>Total number of voting rights held in issuer</span></p></td></tr><tr><td><p class=\"\"><span>Resulting situation on the date on which threshold was crossed or reached</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>12945414</span></p></td></tr><tr><td><p class=\"\"><span>Position of previous notification (if applicable)</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</span></p><p class=\"\"><span>8A. Voting rights attached to shares</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class/Type of shares ISIN code(if possible)</span></p></td><td><p class=\"\"><span>Number of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>Number of indirect voting rights (DTR5.2.1)</span></p></td><td><p class=\"\"><span>% of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>% of indirect voting rights (DTR5.2.1)</span></p></td></tr><tr><td><p class=\"\"><span>GB00BL9BW044</span></p></td><td><p class=\"\"><span>12945414</span></p></td><td><p class=\"\"><span>0</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td></tr><tr><td><p class=\"\"><span>Sub Total 8.A</span></p></td><td colspan=\"2\"><p class=\"\"><span>12945414</span></p></td><td colspan=\"2\"><p class=\"\"><span>4.990000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B1</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"2\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights that may be acquired if the instrument is exercised/converted</span></p></td><td></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B2</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"3\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Physical or cash settlement</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights</span></p></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>9. Information in relation to the person subject to the notification obligation</span></p><p class=\"\"><span>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Ultimate controlling person</span></p></td><td><p class=\"\"><span>Name of controlled undertaking</span></p></td><td><p class=\"\"><span>% of voting rights if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>Total of both if it equals or is higher than the notifiable threshold</span></p></td></tr><tr><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.100000%</span></p></td></tr><tr><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>10. In case of proxy voting</span></p><p class=\"\"><span>Name of the proxy holder</span></p><p class=\"\"><span>The number and % of voting rights held</span></p><p class=\"\"><span>The date until which the voting rights will be held</span></p><p class=\"\"><span>11. Additional Information</span></p><p class=\"\"><span>12. Date of Completion</span></p><p class=\"\"><span>24/02/2026</span></p><p class=\"\"><span>13. Place Of Completion</span></p><p class=\"\"><span>London, UK</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  HOLUBRWRNVUUUAR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8035Ua:0-reg-frp-advisory-grp-plc-holding-s-in-company/",
            "pub_date": "2026-02-28 02:08:57",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008750:0",
            "title": "Zscaler Is Maintained at Outperform by Mizuho",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:09 GMT) </span></strong><span>Zscaler Price Target Cut to $250.00/Share From $265.00 by Mizuho</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008750:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008746:0",
            "title": "PACS Group Is Maintained at Outperform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:09 GMT) </span></strong><span>PACS Group Price Target Raised to $52.00/Share From $47.00 by RBC Capital</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008746:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008748:0",
            "title": "Nexstar Media Is Maintained at Overweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008748:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1RD:0",
            "title": "Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Flagship-backed Generate Biomedicines' (GENB.O) shares fell 6.25% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.</span></p><p class=\"\"><span>The Somerville, Massachusetts-based company's shares opened at $15, compared with its IPO price of $16. It raised $400 million in its U.S. initial public offering on Thursday, after selling 25 million shares within its marketed range of $15 to $17 apiece. </span></p><p class=\"\"><span>Biotech IPOs have gained momentum as interest rates ease and capital returns to the sector, but the recovery remains uneven, with investors staying selective.</span></p><p class=\"\"><span>Eikon Therapeutics (EIKN.O) and Agomab Therapeutics (AGMB.O), health-sector companies that have recently done IPOs, are both trading below their offer prices as of last close.</span></p><p class=\"\"><span>Generate Biomedicines, which describes itself as a pioneer in applying artificial intelligence to biotechnology and drug design, plans to use much of the IPO’s proceeds to complete two Phase 3 trials of its lead asthma drug, GB‑0895.</span></p><p class=\"\"><span>Its early work includes GB‑0669, a COVID‑19 antibody that showed broad, variant‑resistant activity, though the company has shelved its development in light of changing market conditions for preventive COVID‑19 therapies.</span></p><p class=\"\"><span>Noubar Afeyan, who co-founded drugmaker Moderna and is among the board chairs of Generate, is expected to control 49% of the shares through investment firm Flagship Pioneering. The board also includes Nobel laureate Frances Arnold and Moderna CEO Stéphane Bancel.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1RD:0-generate-biomedicines-shares-fall-6-in-weak-nasdaq-debut-for-drug-developer/",
            "pub_date": "2026-02-28 02:09:09",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "modular_finance:25ddb55b87dec:0",
            "title": "Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Aktieägarna i ExpreS2ion Biotech Holding AB (publ),</span></strong><strong class=\"root-Tkn6WL2y\"><span>org.nr</span></strong><strong class=\"root-Tkn6WL2y\"><span>559033-3729 (\"Bolaget\"), kallas härmed till extra bolagsstämma den 1 april 2026 klockan 09:00 på Mindpark, Rönnowsgatan 8C i Helsingborg. Inpassering och registrering till stämman startar klockan 08:45.</span></strong></p><p class=\"\"><span>Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före bolagsstämman ska ha möjlighet att utöva sin röstratt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Rätt att delta och anmälan</span></strong></p><p class=\"\"><span>Rätt att delta i stämman har den som:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>är införd i den av Euroclear Sweden AB förda aktieboken den 24 mars 2026; och</span></li><li class=\"listItem-bmN0_SHH\"><span>anmält sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under rubriken ”</span><em><span>Anmälan för deltagande personligen eller genom ombud</span></em><span>” senast den 26 mars 2026 eller avget en poströst i enlighet med anvisningarna under rubriken ”</span><em><span>Anvisningar för poströstning</span></em><span>” senast den 26 mars 2026.</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Förvaltarregistrerade aktier</span></strong></p><p class=\"\"><span>Aktieägare som låtit förvaltarregistrera sina aktier måste, för att få delta i extra bolagsstämman och utöva sin rösträtt, tillfälligt inregistrera aktierna i eget namn i aktieboken hos Euroclear Sweden AB (s.k. rösträttsregistrering). Framställningen av bolagsstämmoaktieboken per avstämningsdagen den 24 mars 2026 kommer att beakta rösträttsregistreringar som har gjorts senast den 26 mars 2026. Det innebär att aktieägaren i god tid före denna dag måste begära att förvaltaren genomför sådan rösträttsregistrering.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Anmälan för deltagande personligen eller genom ombud</span></strong></p><p class=\"\"><span>Den som önskar delta vid stämman personligen eller genom ombud ska anmäla detta till Bolaget senast den 26 mars 2026 till ExpreS2ion Biotech Holding AB (publ), \"EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, eller via e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>. Vid anmälan ska aktieägaren uppge namn, adress, telefonnummer (dagtid), person- /organisationsnummer, aktieinnehav samt antal eventuella ombud/biträden.</span></p><p class=\"\"><span>Den som inte önskar närvara personligen och inte heller utöva sin rösträtt genom poströstning får utöva sin rätt vid stämman genom ombud med skriftlig, undertecknad och daterad fullmakt. Fullmakten får inte vara äldre än ett år, såvida inte längre giltighetstid (dock längst fem år) har angivits i fullmakten. Om fullmakten utfärdats av en juridisk person ska kopia av registreringsbevis eller motsvarande behörighetshandling för den juridiska personen bifogas. För att underlätta inpasseringen vid stämman bör fullmakter, registreringsbevis och andra behörighetshandlingar skickas antingen per e-post tillinvestor@expres2ionbio.commed referensen \"EGM 2026\" alternativt per post till ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden, att: Keith Alexander, senast den 26 mars 2026. Observera att anmälan om deltagande vid stämman ska ske även om aktieägaren önskar utöva sin rösträtt vid stämman genom ombud. Inskickad fullmakt gäller inte som anmälan till stämman. Fullmaktsformulär på svenska och engelska finns på Bolagets webbplats,investor.expres2ionbio.com.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Anvisningar för poströstning</span></strong></p><p class=\"\"><span>Aktieägare som önskar utöva sin rösträtt genom poströstning ska använda det poströstningsformulär och följa de anvisningar som finns tillgängliga på Bolagets webbplats,investor.expres2ionbio.com. Poströsten måste vara Bolaget tillhanda senast den 26 mars 2026. Poströstningsformuläret ska skickas till ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, alternativt per e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>med referensen \"EGM 2026\".</span></p><p class=\"\"><span>Om aktieägare avger poströst genom ombud ska en skriftlig och daterad fullmakt biläggas poströstningsformuläret. Fullmaktsformulär tillhandhålls på begäran och finns även tillgängligt på Bolagets webbplats,investor.expres2ionbio.com. Om aktieägaren är en juridisk person ska registreringsbevis eller motsvarande behörighetshandling för den juridiska personen bifogas. Aktieägare får inte förse poströsten med särskilda instruktioner eller villkor. Om så sker är hela poströsten ogiltig. Ytterligare anvisningar och villkor finns i poströstningsformuläret.</span></p><p class=\"\"><span>För frågor om stämman eller för att erhålla ett poströstningsformulär eller ett fullmaktsformulär per post, vänligen kontakta ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, alternativt per e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Förslag till dagordning</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Stämmans öppnande och val av ordförande vid stämman</span></li><li class=\"listItem-bmN0_SHH\"><span>Upprättande och godkännande av röstlängd</span></li><li class=\"listItem-bmN0_SHH\"><span>Val av en eller två justeringsmän</span></li><li class=\"listItem-bmN0_SHH\"><span>Prövande av om stämman blivit behörigen sammankallad</span></li><li class=\"listItem-bmN0_SHH\"><span>Godkännande av dagordning</span></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om ändring av bolagsordningen samt minskning av aktiekapitalet för att möjliggöra den avsedda företrädesemissionen av units</span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Styrelsens förslag till beslut om ändring av § 4 i bolagsordningen</span></li><li class=\"listItem-bmN0_SHH\"><span>Styrelsens förslag till beslut om minskning av aktiekapitalet</span></li></ul></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om ändring av bolagsordningen</span></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler och/eller teckningsoptioner</span></li><li class=\"listItem-bmN0_SHH\"><span>Fastställande av arvoden till styrelsen</span></li><li class=\"listItem-bmN0_SHH\"><span>Val av ny styrelseledamot</span></li><li class=\"listItem-bmN0_SHH\"><span>Stämmans avslutande</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 1 – Val av ordförande vid stämman</span></strong></p><p class=\"\"><span>Styrelsen föreslår att advokat Emil Hedberg, eller vid dennes förhinder den som styrelsen i stället anvisar, ska väljas till ordförande vid stämman.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 – Beslut om ändring av bolagsordningen samt minskning av aktiekapitalet för att möjliggöra den avsedda företrädesemissionen av units</span></strong></p><p class=\"\"><em><span>Allmän information om styrelsens förslag enligt punkt 6</span></em></p><p class=\"\"><span>I enlighet med det pressmeddelande som Bolaget offentliggjorde den 27 februari 2026 har styrelsen för avsikt att besluta om en företrädesemission av units om cirka 53 MSEK (”</span><strong class=\"root-Tkn6WL2y\"><span>Företrädesemissionen</span></strong><span>”). Teckningskursen per unit i Företrädesemissionen ska motsvara en TERP-rabatt om minst 35 procent i relation till den volymvägda genomsnittskursen för Bolagets aktie på Nasdaq First North Growth Market under perioden från och med den 24 mars 2026 till och med den 6 april 2026, dock högst 5 SEK och inte lägre än det nya kvotvärdet för Bolagets aktie (1,6 SEK för det fall bolagsstämman beslutar i enlighet med punkt 6). För att möjliggöra genomförandet av Företrädesemissionen föreslås stämman besluta om minskning av aktiekapitalet och justering av aktiekapitalets gränser i bolagsordningen. Ärendena under punkterna 6 a) – b) utgör ett samlat förslag och ska behandlas av bolagsstämman genom ett beslut. Beslut enligt denna punkt 6 är villkorat av att stämman även beslutar enligt punkterna 7 och 8 samt att styrelsen beslutar att genomföra Företrädesemissionen.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt denna punkt 6 erfordras biträde av aktieägare som representerar minst två tredjedelar av såväl de avgivna rösterna som de vid bolagsstämman företrädda aktierna.</span></p><p class=\"\"><em><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 a) – Styrelsens förslag till beslut om ändring av § 4 i bolagsordningen</span></strong></em></p><p class=\"\"><em><span>För att möjliggöra aktiekapitalsminskningen under punkt 6 b) föreslår styrelsen att bolagsstämman beslutar att ändra gränserna för aktiekapitalet enligt § 4 i bolagsordningen enligt följande.</span></em></p><p class=\"\"><em><span>§ 4 i bolagsordningen föreslås erhålla följande lydelse.</span></em></p><p class=\"\"><em><span>Nuvarande lydelse</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 8 000 000 kronor och högst 32 000 000 kronor.</span></p><p class=\"\"><em><span>Föreslagen lydelse</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 b) – Styrelsens förslag till beslut om minskning av aktiekapitalet</span></strong></em></p><p class=\"\"><span>Styrelsen föreslår att bolagsstämman beslutar om minskning av Bolagets aktiekapital med 10 041 551,672912 kronor. Minskningen ska genomföras utan indragning av aktier. Minskningsbeloppet ska användas för avsättning till fritt eget kapital. Minskningen genomförs för att minska aktiernas kvotvärde och för att möjliggöra Företrädesemissionen. Efter minskningen kommer Bolagets aktiekapital att uppgå till 5 648 372,80 kronor fördelat på sammanlagt 3 530 233 aktier (före Företrädesemissionen), envar aktie med ett kvotvärde om 1,6 kronor.</span></p><p class=\"\"><em><span>Styrelsens redogörelse enligt 20 kap 13 § fjärde stycket aktiebolagslagen</span></em></p><p class=\"\"><span>Effekten av styrelsens förslag är att Bolagets aktiekapital minskar med 10 041 551,672912 kronor, från 15 689 924,472912 kronor till 5 648 372,80 kronor. Styrelsen avser samtidigt, med stöd av emissionsbemyndigandet enligt punkt 8 besluta om Företrädesemissionen om cirka 53 miljoner kronor vilken är säkerställd till cirka 60 procent. Teckningskursen per unit i Företrädesemissionen ska motsvara en TERP-rabatt om minst 35 procent i relation till den volymvägda genomsnittskursen för Bolagets aktie på Nasdaq First North Growth Market under perioden från och med den 24 mars 2026 till och med den 6 april 2026, dock högst 5 SEK och inte lägre än det nya kvotvärdet för Bolagets aktie (1,6 SEK för det fall bolagsstämman beslutar i enlighet med punkt 6). Aktiekapitalsminskningen och genomförandet av Företrädesemissionen är villkorade av varandra. Genom att genomföra Företrädesemissionen kommer aktiekapitalet i Bolaget att, i samband med att aktiekapitalsminskningen registreras vid Bolagsverket, samtidigt öka med minst det belopp som aktiekapitalet minskats med. Genom att samtidigt med minskningen genomföra Företrädesemissionen får Bolaget verkställa minskningsbeslutet utan tillstånd från Bolagsverket eller allmän domstol, eftersom åtgärderna sammantaget medför att varken Bolagets bundna egna kapital eller dess aktiekapital minskar.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 – Beslut om ändring av bolagsordningen</span></strong></p><p class=\"\"><span>Styrelsen föreslår att stämman beslutar om ändring av bolagsordningen enligt förslagen i punkterna 7 a), 7 b) och 7 c) nedan för att möjliggöra Företrädesemissionen.</span></p><p class=\"\"><span>Beslut enligt punkterna 7 a) - 7 c) nedan är villkorat av, och ska anmälas för registrering vid Bolagsverket efter, att Bolaget har beslutat om Företrädesemissionen. Vidare föreslår styrelsen att styrelsen bemyndigas att anmäla för registrering vid Bolagsverket den bolagsordning enligt punkt 7 a), punkt 7 b) eller punkt 7 c) vars gränser för det lägsta och högsta antalet aktier och aktiekapitalet i Bolaget är förenliga med det totala antalet aktier och aktiekapitalet i Bolaget efter att styrelsen har beslutat om Företrädesemissionen. För det fall det totala antalet aktier och aktiekapitalet i Bolaget efter att styrelsen har beslutat om Företrädesemissionen är förenlig med ändringarna av bolagsordningen enligt samtliga eller några av punkterna 7 a) - 7 c) nedan ska den bolagsordning som anger det högsta antalet aktier och aktiekapitalet i Bolaget anmälas för registrering.</span></p><p class=\"\"><span>Beslut enligt denna punkt 7 är villkorat av att stämman även beslutar i enlighet med punkterna 6 och 8.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt punkterna 7 a) - c) ovan fordras att beslutet biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 a) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 13 440 000 kronor och högst 53 760 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 8 400 000 och högst 33 600 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 b) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 26 880 000 kronor och högst 107 520 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 16 800 000 och högst 67 200 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 c) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 53 760 000 kronor och högst 215 040 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 33 600 000 och högst 134 400 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 8 - Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler och/eller teckningsoptioner</span></strong></p><p class=\"\"><span>Styrelsen föreslår att extra bolagsstämman beslutar att bemyndiga styrelsen att intill nästa årsstämma, vid ett eller flera tillfällen, besluta om nyemission av aktier, konvertibler och/eller teckningsoptioner, med eller utan avvikelse från aktieägares företrädesrätt, att betalas kontant, genom apport och/eller genom kvittning. Beslut som fattas med stöd av detta emissionsbemyndigande, och där teckningskursen understiger aktiernas kvotvärde per dagen för denna kallelse, är villkorade av att extra bolagsstämman även beslutar i enlighet med förslaget under punkt 6 och punkt 7 ovan och att dessa beslut samtidigt registreras vid Bolagsverket.</span></p><p class=\"\"><span>Att styrelsen ska kunna fatta beslut om emission utan företrädesrätt för aktieägarna enligt ovan är främst i syfte att kunna anskaffa nytt kapital för att bredda Bolagets ägarbas, öka Bolagets flexibilitet, erläggande av betalning för garantiåtaganden i form av units eller i samband med förvärv. I den mån emission sker med avvikelse från aktieägarnas företrädesrätt ska emissionen ske på sedvanliga marknadsmässiga villkor. Om styrelsen finner det lämpligt för att möjliggöra leverans av aktier i samband med en emission enligt ovan kan detta göras till ett teckningspris motsvarande aktiernas kvotvärde.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt denna punkt 8 erfordras biträde av aktieägare som representerar minst två tredjedelar av såväl de avgivna rösterna som de vid bolagsstämman företrädda aktierna.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 9 – Fastställande av arvoden till styrelsen</span></strong></p><p class=\"\"><span>Aktieägarna Allan Rosetzsky, AR CONSULT ApS, Martin Roland Holding ApS och Medic-Advice ApS (\"</span><strong class=\"root-Tkn6WL2y\"><span>Aktieägarna</span></strong><span>\") föreslår att styrelsearvode ska utgå i enlighet med arvodesnivåerna som beslutades av årsstämman 2025, proportionerligt i förhållande till mandattidens längd.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 10 – Val av styrelseledamöter</span></strong></p><p class=\"\"><span>Aktieägarna föreslår omval av Martin Roland Jensen (ordförande), Karin Garre och Jakob Knudsen samt nyval av Michel J. Baijot som styrelseledamöter för tiden intill slutet av nästa årsstämma. Om stämman beslutar i enlighet med Aktieägarnas förslag kommer styrelsen, för tiden intill slutet av nästa årsstämma, att bestå av Martin Roland Jensen (ordförande), Karin Garre, Jakob Knudsen och Michel J. Baijot.</span></p><p class=\"\"><em><span>Information om Michel J. Baijot</span></em></p><p class=\"\"><em><span>Född:</span></em><span>1961.</span></p><p class=\"\"><em><span>Utbildning:</span></em><span>Bioingenjör, doktorsexamen i molekylärbiologi från University of Louvain (Belgien).</span></p><p class=\"\"><em><span>Bakgrund:</span></em><span>Michel Baijot har tillbringat mer än 25 år i olika ledande befattningar hos bioMerieux som Corporate Director Molecular Diagnostics, hos Innogenetics som VP of Business Development, hos GSK Vaccines som VP of strategy, licensing and M&amp;A, hos Janssen Crucell Vaccines som Chief Business Officer och hos Serum Institute of India som Executive Director Europe. Han har varit ordförande för Belgian Biotech Association i 5 år.</span></p><p class=\"\"><em><span>Pågående uppdrag</span></em><span>: Styrelseordförande i White Fund, styrelseledamot i RNAlead, Director på Noshaq samt styrelseordförande i CuraVac.</span></p><p class=\"\"><em><span>Oberoende</span></em><span>: Michel J. Baijot är oberoende i förhållande till Bolaget och Bolagets ledning samt i förhållande till Bolagets större aktieägare.</span></p><p class=\"\"><em><span>Aktieägande</span></em><span>: Michel J. Baijot innehar inga aktier i Bolaget per dagen för denna kallelse.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Handlingar</span></strong></p><p class=\"\"><span>Fullmaktsformulär, poströstningsformulär och övriga handlingar enligt aktiebolagslagen kommer att finnas tillgängliga vid Bolagets kontor på Mindpark, Bredgatan 11 i Helsingborg samt på Bolagets webbplats,www.investor.expres2ionbio.com, senast två veckor före stämman. Handlingarna skickas också till de aktieägare som önskar detta och uppger sin postadress.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Aktieägarnas frågerätt</span></strong></p><p class=\"\"><span>Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap 32 § aktiebolagslagen.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Behandling av personuppgifter</span></strong></p><p class=\"\"><span>För information om hur dina personuppgifter behandlas hänvisas till den integritetspolicy som finns tillgänglig på Euroclears webbplats:www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.</span></p><p class=\"\"><span>______________</span></p><p class=\"\"><span>Helsingborg i februari 2026</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>ExpreS2ion Biotech Holding AB (publ)</span></strong></p><p class=\"\"><em><span>Styrelsen</span></em></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Attachments</span></strong></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://storage.mfn.se/30418de7-3222-49e3-8365-cd944744df8e/kallelse-till-extra-bolagsstamma-i-expres2ion-biotech-holding-ab-publ.pdf\" rel=\"nofollow\" target=\"_blank\">Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/modular_finance:25ddb55b87dec:0-kallelse-till-extra-bolagsst-mma-i-expres2ion-biotech-holding-ab-publ/",
            "pub_date": "2026-02-28 02:10:00",
            "source": "MFN by Modular Finance",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008663:0",
            "title": "Relay Therapeutics Is Maintained at Overweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:00 GMT) </span></strong><span>Relay Therapeutics Price Target Raised to $15.00/Share From $13.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008663:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa7693Ua:0",
            "title": "REG - FTSE Russell Invesco Glbl. Equity - Invesco Global Equity Income Trust",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 7693U  FTSE Russell  27 February 2026   </span><p class=\"\"></p><p class=\"\"></p><p class=\"\"><span>47</span></p><p class=\"\"><span>Franklin Global Trust (UK): Scheme of Reconstruction into Invesco Global Equity Income Trust (UK)</span></p><p class=\"\"><span>Changes in FTSE UK Index Series</span></p><p class=\"\"><span>27 February 2026</span></p><p class=\"\"></p><p class=\"\"><span>Further to the FTSE Russell notice published on 10 February 2026 and following the publication of the stock terms and election results of the scheme of reconstruction between Franklin Global Trust (UK, constituent) and Invesco Global Equity Income Trust (UK, constituent), please see details of affected indexes and effective dates below:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><thead><tr><td><p class=\"\"><span>Index</span></p></td><td><p class=\"\"><span>Effective From</span></p><p class=\"\"><span>Start of Trading</span></p></td></tr></thead><tbody><tr><td><p class=\"\"><span>FTSE SmallCap Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Share Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Share ex Multinationals Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Small Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr></tbody></table></div><p class=\"\"></p><p class=\"\"><span>For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Australia</span></p></td><td><p class=\"\"><span>+61 (0) 2 7228 5659</span></p></td></tr><tr><td><p class=\"\"><span>Hong Kong</span></p></td><td><p class=\"\"><span>+852 2164 3333</span></p></td></tr><tr><td><p class=\"\"><span>Japan</span></p></td><td><p class=\"\"><span>+81 3 6441 1430</span></p></td></tr><tr><td><p class=\"\"><span>London</span></p></td><td><p class=\"\"><span>+44 (0) 20 7866 1810</span></p></td></tr><tr><td><p class=\"\"><span>New York</span></p></td><td><p class=\"\"><span>+1877 503 6437</span></p></td></tr></tbody></table></div><p class=\"\"><span>Alternatively please visit our website at lseg.com/ftse-russell</span></p><p class=\"\"><span> Terms of Use | Copyright © 2026 FTSE Russell</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  FTSBXGDDGXDDGLR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa7693Ua:0-reg-ftse-russell-invesco-glbl-equity-invesco-global-equity-income-trust/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008665:0",
            "title": "Natera Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:00 GMT) </span></strong><span>Natera Price Target Raised to $215.00/Share From $205.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008665:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZM155:0",
            "title": "Mexico corporate earnings week ahead",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Please be advised that there are no corporate earnings scheduled for Mexico (.MXX) in the week ahead.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZM155:0-mexico-corporate-earnings-week-ahead/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008667:0",
            "title": "GoodRx Holdings Is Maintained at Neutral by Mizuho",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:00 GMT) </span></strong><span>GoodRx Holdings Price Target Cut to $3.00/Share From $4.00 by Mizuho</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008667:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_SN20260227012761:0",
            "title": "Did Paramount overpay and Netflix get away scot-free? Taking stock of the Warner Bros. deal.",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>By Lukas I. Alpert</span></p><p class=\"\"><span>Paramount must now absorb a troubled asset at a high cost, while Netflix investors seem overjoyed to not have such problems</span></p><p class=\"\"><span>Paramount Skydance is paying a huge price for Warner Bros. Discovery after Netflix backed away at a time of great unsteadiness for Hollywood and the television industry.</span></p><p class=\"\"><span>So what exactly did Paramount Skydance just buy for $111 billion?</span></p><p class=\"\"><span>The optimistic view is that the substantial assets of Warner Bros. Discovery (WBD) will help Paramount (PSKY) transform two \"subscale\" media businesses into one major contender.</span></p><p class=\"\"><span>The more pessimistic take is that the newly combined company has now saddled itself with a crushing amount of debt - the deal is being described as the biggest leveraged buyout in history - and will require even more intensive capital expenditures to make the whole thing work.</span></p><p class=\"\"><span>History is littered with examples of big media mergers going awry, many of them involving some permutation of Warner Bros.: AOL and Time Warner, for instance, as well as AT&amp;T (T) and Time Warner. But the last major media buyout, Walt Disney Co.'s (DIS) 2019 acquisition of 21st Century Fox for $71 billion, has been generally considered more successful.</span></p><p class=\"\"><span>Netflix (NFLX) surprised many by bowing out so quickly in the fight for a deal it seemed to have pretty well locked up at the beginning of the week. But judging by the reaction from shareholders, Netflix may ultimately have saved itself from some complex problems - while collecting a $2.8 billion breakup fee for its troubles.</span></p><p class=\"\"><span>Whatever the view, investors seem happy with the result. Netflix shares were surging 10.6% in recent midday trading toward their highest closing price this year. The stock has shot up 20.2% amid a four-day winning streak.</span></p><p class=\"\"><span>Paramount shares soared 20.4%, also to their highest price this year, while Warner Bros. shares were down around 2%.</span></p><p class=\"\"><span>Netflix said in a statement Thursday that it viewed Warner Bros as \"'nice to have' at the right price, not a 'must have' at any price.\" But the market had taken a dim view of the deal, with Netflix's share price down as much as 30% since it announced its deal with Warner Bros. in December.</span></p><p class=\"\"><span>\"The strong Paramount bid provided a convenient out for Netflix,\" said Paul Nary, a management professor at the Wharton School, pointing to the level of market discontent along with the specter of regulatory pressure from the Trump administration, which had expressed displeasure with the Netflix deal.</span></p><p class=\"\"><span>Analysts say they expect Netflix to now commit itself more aggressively to acquiring sports rights and other content. The company has said it intends to spend $20 billion on content this year.</span></p><p class=\"\"><span>For Paramount, sealing the deal, even at such a high price, may have been less of a choice than a necessity if it wants to survive in a rapidly changing media landscape.</span></p><p class=\"\"><span>\"While the war for Warner Bros. Discovery ended sooner than expected, this result confirms our ongoing view that [Warner Bros.] was a necessity for [Paramount] while Netflix was being opportunistic,\" media analyst Robert Fishman of MoffetNathanson wrote in a note to clients. \"We believe the future Paramount Skydance Warner Bros. Discovery ... could finally transform two subscale media companies into a more serious industry player, provided management has the financial flexibility to execute on its vision.\"</span></p><p class=\"\"><span>That last part will be key in order for Paramount and its principal owners - CEO David Ellison and his father, Oracle (ORCL) co-founder Larry Ellison, who is one of the richest people in the world - to make the merger a success.</span></p><p class=\"\"><span>If the deal is ultimately approved, Paramount will be tasked with absorbing a company that has struggled for years, booking considerable losses in 12 of the 14 quarters since Warner Media merged with Discovery in 2022.</span></p><p class=\"\"><span>Together, Paramount and Warner Bros. Discovery count over 210 million streaming subscribers and collectively reach about 19% of the U.S. market, putting them ahead of Disney+, nearly on par with Amazon's Prime Video and just behind market leader Netflix.</span></p><p class=\"\"><span>But both Warner Bros. and Paramount have seen continual declines in every other aspect of their businesses as the movie and television industries undergo a period of radical change.</span></p><p class=\"\"><span>Warner Bros. closed out 2025 with $37.3 billion in revenue, down 5% from the year before, despite a banner year for its studio business. For its studio and HBO Max streaming businesses this year, the company saw strong gains in adjusted earnings before interest, taxes, depreciation and amortization, a widely followed measure of underlying profitability.</span></p><p class=\"\"><span>But its rapidly declining television unit, which includes brands like CNN, Discovery and the Cartoon Network and brings in almost half the company's revenue, saw its adjusted Ebitda fall 21% in 2025. Revenue for the division fell 12% last year.</span></p><p class=\"\"><span>Paramount, which only in August closed a deal to merge with David Ellison's Skydance for $8 billion, took in $28.9 billion in revenue last year, down 1% from 2024. It has also booked net losses in five of its last eight quarters.</span></p><p class=\"\"><span>The company swung to a $230 million gain in operating income before depreciation and amortization - another profitability measure - for its Paramount+ streaming business in 2025, compared with a $497 million loss the year before. But it also recorded a 15% decline in adjusted Oibda for its television business in 2025 from the year before and an increased Oibda loss of $232 million for its film studio year over year.</span></p><p class=\"\"><span>David Ellison has promised that the combined company will be able to put out 30 films a year going forward - a huge cost increase from the combined total of 20 that the two companies made last year.</span></p><p class=\"\"><span>With Netflix out of the way, Paramount now has to turn to gaining regulatory approval for its deal, which most analysts expect will not encounter too much difficulty given the Ellisons' good relationship with the Trump administration.</span></p><p class=\"\"><span>The deal, however, could face some roadblocks from various state attorneys general and possibly in Europe, which could slow things down and cost Paramount even more money. As part of its deal, it has agreed to pay an additional 25 cents per share for every quarter the merger doesn't close past Sept. 30 of this year.</span></p><p class=\"\"><span>\"We see [the Department of Justice] approving the deal and state [attorneys general] challenging it in court. But if DOJ does in fact support the deal, we think that would persuade a judge to approve the merger over states' objections,\" analyst Paul Gallant with TD Securities wrote in a note to clients. \"Most importantly, President Trump presumably wants Paramount to own CNN. So we do anticipate DOJ approval, perhaps with conditions.\"</span></p><p class=\"\"><span>-Lukas I. Alpert</span></p><p class=\"\"><span>This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_SN20260227012761:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "MarketWatch",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008648:0",
            "title": "Credit Fears Are Spreading to Consumer Lending — WSJ",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>By Telis Demos</span></p><p class=\"\"><span>The market's fears about loans aren't limited to what's happening with private credit.</span></p><p class=\"\"><span>Many headlines on Friday were focused on dividend cuts at business-development companies, which typically lend to privately-held, mid-sized companies.</span></p><p class=\"\"><span>Yet shares of consumer lenders were tumbling sharply on Friday, even without much data showing significant strain there yet.</span></p><p class=\"\"><span>Student-lender SLM Corp., online lenders LendingClub and Upstart, buy now-pay later provider Affirm and card giants American Express, Capital One Financial and Synchrony Financial were all down at least 6% on Friday.</span></p><p class=\"\"><span>\"Investors remain on edge about the credit environment,\" Jefferies consumer-lending analysts wrote in a note on Thursday evening.</span></p><p class=\"\"><span>The analysts wrote that \"credit remains stable\" broadly across fintech lenders, with many delinquency rates still falling year-over-year.</span></p><p class=\"\"><span>However, an overall slowing of improvements to that trend is contributing to investors' concern, they said. Another worry has been a slowdown in lending volume growth from last year.</span></p><p class=\"\"><span>Also on Thursday, VantageScore reported that its CreditGauge tracker was seeing sharp increases in early-stage credit delinquencies across all tiers of borrowers in January, with the sharpest increase actually coming among well-heeled \"superprime\" consumers.</span></p><p class=\"\"><span>To be sure, late-payment rates were not especially elevated. For example, the early-stage delinquency rate for superprime borrowers was still below 0.01%.</span></p><p class=\"\"><span>However, \"sustained cost pressures and interest rates may leave some consumers increasingly exposed to future economic shocks,\" VantageScore Chief Digital, Data and Technology Officer Susan Fahy said in a statement.</span></p><p class=\"\"><span>At least some investors seem to think those risks aren't so remote.</span></p><p class=\"\"><span>This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008648:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008640:0",
            "title": "Autodesk CEO Brushes Off AI Displacement Fears: 'Our Moat's Very Deep' — Interview",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>By Elias Schisgall</span></p><p class=\"\"><span>Autodesk Chief Executive Andrew Anagnost isn't stressing about the selloff in software stocks, including his own, driven by fears of artificial-intelligence in the software industry.</span></p><p class=\"\"><span>The head of the digital design software company brushed off fears that Autodesk would be displaced by an AI-native competitor. Instead, he feels that the company's products have enough of an edge for it to become an AI winner.</span></p><p class=\"\"><span>Investors are \"still trying to figure out who's got the strong moats,\" Anagnost said in an interview. \"They're selling off across the sector and then backing up and watching to see how the sector responds over time.\"</span></p><p class=\"\"><span>\"Our moat's very deep,\" he added.</span></p><p class=\"\"><span>Anagnost's comments come as investors have grown increasingly wary of traditional software-as-a-service companies, fearing that AI-native firms will be able to offer similar services faster and cheaper.</span></p><p class=\"\"><span>Software stocks plunged earlier this month after Anthropic released a set of add-ons to its Claude model, including a legal research assistant. A viral report from Citrini Research outlining a potential doomsday scenario driven by AI disruption triggered another selloff this week. An ETF tracking about 140 software companies has dropped 20% year to date.</span></p><p class=\"\"><span>Shares of Autodesk have taken a hit too, falling 17% to start the year.</span></p><p class=\"\"><span>Anagnost said Autodesk will be differentiated by its context and expertise around the full design and construction process, as well as its in-house AI talent focused specifically on implementation in 3D, design and construction settings.</span></p><p class=\"\"><span>He added that Autodesk has a trove of data on real-world design workflows and assets that has allowed it to build proprietary AI models for its products.</span></p><p class=\"\"><span>\"We use these in conjunction with the frontier models, but we're always staying ahead of what the frontier models can do on their own,\" Anagnost said.</span></p><p class=\"\"><span>Anagnost added he remains confident in Autodesk's subscription-based model, especially given the multi-year nature of construction projects and the increased pricing power from more AI capabilities per subscription seat. Autodesk's fourth-quarter results Thursday showed a nearly 20% year-over-year rise in subscription revenue.</span></p><p class=\"\"><span>The company offers a range of other payment models, including a consumption-based model that has been ramping up over the past decade. Autodesk's mix is shifting gradually toward consumption- and product-based payment models, he said.</span></p><p class=\"\"><span>Autodesk is adapting to the AI rush in other ways. The company invested $200 million earlier this month in World Labs, a physical-world AI company that Anagnost described as a necessary alternative to text-based large language models.</span></p><p class=\"\"><span>\"What World Labs is working on is a model that is spatially aware, that's aware of physical interactions, and can react to changes in the physical world,\" he said. \"We think they're going to be a core foundational, horizontal technology - a platform - that we can incorporate in our technology.\"</span></p><p class=\"\"><span>The company also is putting money toward automating parts of its sales organization, especially around subscription renewals, using savings from the layoff of 1,000 employees largely in customer-facing sales functions.</span></p><p class=\"\"><span>The layoffs, Anagnost reiterated, were the final phase of a broader restructuring plan and focused on eliminating duplicated sales work, not to replace humans with AI.</span></p><p class=\"\"><span>Still, he said, Autodesk is increasingly able to automate the subscription renewal process, adding that the company's layoffs were focused on \"overlapping costs associated with renewals.\" He added that the company expects to slow its hiring in the future as it balances investments in technology and staff.</span></p><p class=\"\"><span>A leaner sales organization and ongoing AI investments, Anagnost said, has positioned Autodesk to capitalize on the AI wave rather than letting its services fall by the wayside.</span></p><p class=\"\"><span>\"We invested years - years - in changing our go-to-market and automating our systems and building out our platform so that we're ready for this moment,\" Anagnost said. \"We're spending a lot more time preparing and executing, and not much time worrying.\"</span></p><p class=\"\"><span>Write to Elias Schisgall at elias.schisgall@wsj.com</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008640:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8028Ua:0",
            "title": "REG - Lloyds Banking Group - Transaction in Own Shares",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8028U  Lloyds Banking Group PLC  27 February 2026   </span><p class=\"\"></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"></p><p class=\"\"><span>27 February 2026</span></p><p class=\"\"><span>TRANSACTIONS IN OWN SECURITIES</span></p><p class=\"\"><span>Lloyds Banking Group plc (the \"Company\") announces today that it has purchased the following number of its ordinary shares, from Goldman Sachs International (the \"Broker\").</span></p><p class=\"\"><span>Ordinary Shares</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"></p><p class=\"\"><span>Date of purchases: 27 February 2026</span></p><p class=\"\"><span>Number of ordinary shares purchased: 7,000,000</span></p><p class=\"\"><span>Highest price paid per share (pence): 105.0000</span></p><p class=\"\"><span>Lowest price paid per share (pence): 101.7000</span></p><p class=\"\"><span>Volume weighted average price paid per share (pence): 103.2522</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"></p><p class=\"\"><span>Such purchases form part of the Company's existing share buyback programme and were effected pursuant to the instructions issued to the Broker by the Company on 29 January 2026, as announced on 30 January 2026.</span></p><p class=\"\"><span>The Company intends to cancel these shares.</span></p><p class=\"\"><span>In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (as such legislation forms part of assimilated law as defined in the EU (Withdrawal) Act 2018), a full breakdown of the individual trades made by the Broker on behalf of the Company as part of the buyback programme is set out in the Schedule to this announcement available through the link below:</span></p><p class=\"\"><span>http://www.rns-pdf.londonstockexchange.com/rns/8028U_1-2026-2-27.pdf</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"></p><p class=\"\"><span>Since the commencement of the share buyback programme to repurchase up to £1.75 billion of ordinary shares, as announced on 30 January 2026, the Company has purchased 200,094,019 ordinary shares for a consideration of £208,538,634.69.</span></p></li></ul></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"></p><p class=\"\"><span>- END -</span></p><p class=\"\"><span>For further information:</span></p><p class=\"\"><span>Investor Relations</span></p><p class=\"\"><span>Douglas Radcliffe                                                                                                           +44 (0)20 7356 1571</span></p><p class=\"\"><span>Group Investor Relations Director</span></p><p class=\"\"><span>douglas.radcliffe@lloydsbanking.com</span></p><p class=\"\"><span>Corporate Affairs</span></p><p class=\"\"><span>Matt Smith                                                                                                                      +44 (0)20 7356 3522</span></p><p class=\"\"><span>Head of Media Relations</span></p><p class=\"\"><span>matt.smith@lloydsbanking.com</span></p></li></ul><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  POSDDLFLQLLEBBD</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8028Ua:0-reg-lloyds-banking-group-transaction-in-own-shares/",
            "pub_date": "2026-02-28 02:00:30",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008670:0",
            "title": "Dell Stock on Pace for Best Month Ever. Why It Continues to Be a Tech Winner. — Barrons.com",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>By Angela Palumbo</span></p><p class=\"\"><span>Dell Technologies stock was surging Friday after earnings, as the company's ability to push through headwinds keeps investors excited.</span></p><p class=\"\"><span>Dell reported a knockout quarter after the stock market closed on Thursday, driven by a strong demand for the company's artificial intelligence servers.</span></p><p class=\"\"><span>Even more impressive was its outlook. Dell gave earnings and revenue guidance for the year that handily beat analyst expectations. That came as a pleasant surprise to investors, as tech hardware companies are dealing with rising memory costs that are pressuring margins.</span></p><p class=\"\"><span>Competing personal systems maker HP Inc. said when reporting fiscal first-quarter financials on Tuesday that it expects earnings for the fiscal year to come in at the lower end of guidance due to rising memory costs.</span></p><p class=\"\"><span>Dell has been able to successfully push through these headwinds.</span></p><p class=\"\"><span>\"Yes, DRAM, NAND, HDDs and other component prices are surging but Dell has expertise working with the supply chain, its high-margin storage business is improving and its quick moving price increases seem to be insulating it from the worst\" Melius Research analyst Ben Reitzes wrote on Friday.</span></p><p class=\"\"><span>Reitzes rates Dell as a Buy with a $200 price target. He added that earnings were \"supposed to be a disaster due to components, especially memory. It sure wasn't and Dell should be rewarded.\"</span></p><p class=\"\"><span>Wall Street was rewarding Dell. The stock was surging 20% to $145.65.</span></p><p class=\"\"><span>Shares have risen 25% in February and were on pace for their best month on record, according to Dow Jones Market Data. That climb is in contrast to the broader tech sector. The Nasdaq Composite has fallen 3.2% in February, and was on pace for its largest one-month percentage decline since March 2025.</span></p><p class=\"\"><span>Multiple areas of tech have been experiencing challenges this year, pausing the sector's rally. Investors are concerned that AI could replace software capabilities, leading to a selloff in stocks like Salesforce, ServiceNow, and Adobe.</span></p><p class=\"\"><span>Megacap stocks have hit a wall as Wall Street becomes more cautious about companies like Amazon.com and Microsoft's spending plans. Meanwhile, rising memory costs are putting pressure on tech hardware companies.</span></p><p class=\"\"><span>The Nasdaq Composite has declined 2.3% this year. Dell has risen 17% in 2026.</span></p><p class=\"\"><span>\"Dell has shown itself to be an effective and responsible operator,\" Raymond James analyst Simon Leopold wrote on Thursday. He raised his price target to $182 from $166 and maintained an Outperform rating on the stock.</span></p><p class=\"\"><span>Still, there are risks.</span></p><p class=\"\"><span>\"While the near term is clearly strong, we are unsure of the demand elasticity created by the swift and significant price actions taken by Dell,\" BofA Securities analyst Wamsi Mohan wrote on Thursday.</span></p><p class=\"\"><span>Mohan raised his price target to $155 from $135 while reiterating a Buy rating and said that while memory costs aren't going away anytime soon, and higher prices that are meant to offset those costs could crimp consumer demand, server growth driven by AI demand could offset some of these problems.</span></p><p class=\"\"><span>Meanwhile, Dell looks to be a safe haven as investors figure out a volatile tech environment.</span></p><p class=\"\"><span>Write to Angela Palumbo at angela.palumbo@dowjones.com</span></p><p class=\"\"><span>This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008670:0/",
            "pub_date": "2026-02-28 02:01:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZN2D6:0",
            "title": "Nexa Resources SA reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nexa Resources SA </span><span> reported quarterly adjusted earnings of 60 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.00.  The mean expectation of seven analysts for the quarter was for earnings of 8 cents per share. Wall Street expected results to range from 2 cents to 21 cents per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue rose 3% to $903.00 million from a year ago; analysts expected $773.70 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nexa Resources SA's reported EPS for the quarter was 38 cents​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $50.4 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nexa Resources SA shares had risen by 35.8% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 518.8% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, seven analysts negatively revised earnings estimates</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 5 \"hold\" and 2 \"sell\" or \"strong sell.\" The average consensus recommendation for the specialty mining &amp; metals peer group is  \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Nexa Resources SA is $10.00, about 20.2% below its last closing price of $12.02</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 27 at 06:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2025 </span></p></td><td><p class=\"\"><span>0.47</span></p></td><td><p class=\"\"><span>-0.03</span></p></td><td><p class=\"\"><span>Missed</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>0.06</span></p></td><td><p class=\"\"><span>0.11</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>0.06</span></p></td><td><p class=\"\"><span>0.16</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2024 </span></p></td><td><p class=\"\"><span>0.08</span></p></td><td><p class=\"\"><span>0.16</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZN2D6:0-nexa-resources-sa-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-28 02:01:13",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L6N3ZN110:0",
            "title": "California now the biggest obstacle to Paramount's Warner Bros takeover",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>California investigates Paramount's Warner Bros takeover, citing economic concerns</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Paramount's cost synergies imply job cuts, affecting California's economy</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>California has history of challenging large mergers, often working with federal enforcers</span></li></ul></span></div><span><p class=\"\"><span>By Jody Godoy</span></p><p class=\"\"><span>    California has a lot to lose if Paramount Skydance </span><span> buys Warner Bros Discovery </span><span> and could stand in the way of a deal, while Paramount's deep political connections to the Trump administration are expected to smooth the path to federal regulatory approval.</span></p><p class=\"\"><span>State Attorney General Rob Bonta said on Thursday that California is already investigating the deal and will be \"vigorous\" in its review. Hours earlier, Paramount beat out streaming giant Netflix </span><span> in a months-long battle for control of the storied Hollywood studio.</span></p><p class=\"\"><span>Paramount's bid is likely to raise concerns about job cuts in California that also dogged Netflix's bid. Paramount sees $6 billion in cost \"synergies\" in the deal, which is often code for massive layoffs and cutting, or sharply paring back, entire units. It can also mean reducing the number of suppliers and squeezing existing contractors for better terms after the two companies merge. None of that is good news for the California economy.</span></p><p class=\"\"><span>While Paramount initially came in with what the Warner Bros board viewed as an inferior offer, it was highly successful in stirring up political opposition to Netflix's bid among Republicans in Washington. Now, Bonta and California Governor Gavin Newsom, both Democrats, are expected to be the biggest hurdles to Paramount after the media conglomerate won the fight by upping its offer price.</span></p><p class=\"\"><span>    Any delays could add to the price tag of the deal valued at $110 billion. Paramount has bet on closing quickly, promising to pay Warner Bros shareholders a 25-cent per share quarterly \"ticking fee\" starting in October if the deal has not closed.</span></p><p class=\"\"><span>Spokespeople for Warner Bros and Paramount did not immediately respond to requests for comment.</span></p><p class=\"\"><span>State intervention to block the deal is \"very likely,\" TD Cowen analysts said in a note on Thursday, adding that \"approval from federal regulators seems likely given the political environment.\"</span></p><p class=\"\"><span>Newsom, a potential 2028 presidential candidate, has gone out of his way to present himself as a leader among the political opposition to President Donald Trump. Bonta has sued the federal government repeatedly over Trump administration decisions on issues such as clean energy, pipeline projects and health funding.</span></p><p class=\"\"><span>U.S. Senator Adam Schiff, a California Democrat, said on Thursday that \"what was true for Netflix is still true now for Paramount,\" calling for the deal to face \"the highest levels of scrutiny.\"</span></p><p class=\"\"><span>     HOLLYWOOD LABOR CRITICIZES DEAL</span></p><p class=\"\"><span>     The Writers Guild of America, a union representing thousands of television and film writers along with other media workers, has said a Paramount takeover of Warner Bros would hurt jobs. Warner Bros canceled $2 billion in content after merging with Discovery in 2022, and Paramount's recent merger with Skydance led to 1,000 layoffs, the union said in written testimony to the U.S. Senate.</span></p><p class=\"\"><span>        Academy Award-winning actor Mark Ruffalo posted on social media site X on Friday that states should hear from Hollywood on how the deal would harm competition, hurt quality for consumers and drive down wages. </span></p><p class=\"\"><span>        \"There are lots of agents in Hollywood who can tell you how past mergers and consolidations have hurt their clients and business. There is lots of talent that can tell you the same,\" he said.</span></p><p class=\"\"><span>        CALIFORNIA EXPERIENCED AT BLOCKING MERGERS</span></p><p class=\"\"><span>After California probes the deal, it can file a lawsuit seeking to block the transaction. If the court agrees the deal would unlawfully harm competition, it will enter an order preventing it from closing. The parties could then decide to stretch out the process and appeal the ruling, abandon the deal, or negotiate a settlement.         </span></p><p class=\"\"><span>California has challenged large mergers in the past. In 2019, it co-led a group of states challenging T-Mobile's </span><span> acquisition of Sprint. While the states lost in court, California secured a settlement recouping its costs and getting temporary commitments to keep jobs in place and offer low-cost plans for consumers.</span></p><p class=\"\"><span>California also joined the Federal Trade Commission and several other states in a successful bid to block Kroger's </span><span> takeover of rival grocery chain Albertsons.</span></p><p class=\"\"><span>While the state often works with federal enforcers, Bonta's office has also levied criticisms against some settlements that cleared the way for mergers. For example, it is part of a coalition of 13 states opposing a Justice Department settlement allowing Hewlett Packard Enterprise's </span><span> $14 billion acquisition of Juniper Networks.</span></p><p class=\"\"><span>Over the past few years, Bonta's office has staffed up on competition enforcers under the leadership of antitrust head Paula Blizzard. A longtime state antitrust enforcer, Blizzard previously worked at the DOJ and at the Federal Communications Commission, which enforces federal regulations on broadcasters.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L6N3ZN110:0-california-now-the-biggest-obstacle-to-paramount-s-warner-bros-takeover/",
            "pub_date": "2026-02-28 02:01:15",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L6N3ZN149:0",
            "title": "Q4 US earnings growth now seen above 14%; Broadcom up next week",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Main US indexes red; Dow, Nasdaq both down &gt;1%</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Financials weakest S&amp;P 500 sector; Energy leads gainers</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Dollar slips; bitcoin down &gt;2%; gold up ~1%; crude up &gt;2%</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>US 10-Year Treasury yield falls to ~3.97%</span></li></ul></span></div><span><p class=\"\"><span>Q4 US EARNINGS GROWTH NOW SEEN ABOVE 14%; BROADCOM UP NEXT WEEK</span></p><p class=\"\"><span>Year-over-year estimated earnings growth for S&amp;P 500 </span><span> companies in the fourth quarter of 2025 broke above 14% in the past week, according to LSEG data Friday.</span></p><p class=\"\"><span>Nvidia's </span><span> late Wednesday results surpassed high analyst expectations, but its stock has fallen sharply in the wake of the report amid concerns over overall artificial intelligence demand.</span></p><p class=\"\"><span>With results in now from 479 of the S&amp;P 500 companies, estimated earnings growth is at 14.3%, up from 13.9% a week ago.</span></p><p class=\"\"><span>That 14.3% growth would still be below the 14.9% earnings growth for S&amp;P 500 companies in the third quarter of 2025.</span></p><p class=\"\"><span>Earnings growth for the technology sector </span><span> is now seen at 33.8%, up from 26.5% at the start of January, LSEG data showed.</span></p><p class=\"\"><span>Among companies still to report is Broadcom </span><span>, whose results will be among the last of the fourth-quarter earnings season.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L6N3ZN149:0-q4-us-earnings-growth-now-seen-above-14-broadcom-up-next-week/",
            "pub_date": "2026-02-28 02:01:16",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_EM15vXz6a:0",
            "title": "KERNEL HOLDING S.A. - KERNEL HOLDING S.A. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR 6 MONTHS ENDED 31 DECEMBER 2025",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>POLISH FINANCIAL SUPERVISION AUTHORITY</span></p><p class=\"\"><span>UNI - EN REPORT No 4 / 2026</span></p><p class=\"\"><span>Date of issue: 2026-02-27</span></p><p class=\"\"><span>Short name of the issuer</span></p><p class=\"\"><span>KERNEL HOLDING S.A.</span></p><p class=\"\"><span>Subject</span></p><p class=\"\"><span>KERNEL HOLDING S.A. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR 6 MONTHS ENDED 31</span></p><p class=\"\"><span>DECEMBER 2025</span></p><p class=\"\"><span>Official market - legal basis</span></p><p class=\"\"><span>art. 56. 1. 2 of Act on Public Offering.</span></p><p class=\"\"><span>Unofficial market - legal basis</span></p><p class=\"\"><span>Contents of the report:</span></p><p class=\"\"><span>The Board of Directors of Kernel Holding S.A. informs that the Condensed Consolidated Interim</span></p><p class=\"\"><span>Financial Statements for the six months ended 31 December 2025 are published and available on the</span></p><p class=\"\"><span>Company’s website: https://www.kernel.ua/investor-relations/financial-reports/.</span></p><p class=\"\"><span>Annexes</span></p><p class=\"\"><span>File Description</span></p><p class=\"\"><span>Additional attachments can be found below:</span></p><p class=\"\"><span>20260227_185217_1979921044_Kernel_FY2026_H1_report.pdf</span></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260227:nEM13Bjpda\" rel=\"nofollow\" target=\"_blank\">newsfile.refinitiv.com/getnewsfile/v1/story</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_EM15vXz6a:0-kernel-holding-s-a-kernel-holding-s-a-condensed-consolidated-interim-financial-statements-for-6-months-ended-31-december-2025/",
            "pub_date": "2026-02-28 01:52:21",
            "source": "Polish Emitent",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008530:0",
            "title": "Norwegian Must Continue Cutting Costs — Market Talk",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Norwegian Cruise Line has been executing a cost-cutting plan since 2024, but there are opportunities to cut costs even further, say Melius analysts Conor Cunningham and Patrick Coleman. The company has moved to more Caribbean and shorter duration cruises, which \"should allow for additional cost takeout opportunities that have yet to be highlighted,\" the analysts say. The company is now facing activist pressure from Elliot Investment Management, increasing scrutiny on its spending. \"There must be more opportunities to bend down, if not flat-out reduce, non-fuel unit costs in the years to come given prior spending habits and the current shift in the brand mix.\" (nicholas.miller@wsj.com)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008530:0/",
            "pub_date": "2026-02-28 01:53:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008437_20260227008529:0",
            "title": "Metals Royalty Has a Royalty Interest in the NORI Property Operated by TMC The Metals Co.",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008437_20260227008529:0/",
            "pub_date": "2026-02-28 01:53:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "modular_finance:5e9de14dab172:0",
            "title": "EXPRES2ION ANNOUNCES THE BOARD OF DIRECTORS’ INTENTION TO RESOLVE ON A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 53 MILLION",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Hørsholm, Denmark, 27 February 2026 – The Board of Directors of ExpreS2ion Biotech Holding AB (publ) (\"ExpreS2ion\" or the \"Company\") today announces its intention to resolve on a new issue of units with preferential rights for existing shareholders of approximately SEK 53 million before transaction costs (the “Rights Issue”). One (1) unit in the Rights Issue is intended to consist of one (1) new share and one (1) warrant of series TO 13. The Board of Directors’ intention to resolve on the Rights Issue is subject to the shareholders at the extraordinary general meeting intended to be held on 1 April 2026 (the “Extraordinary General Meeting”) authorizing the Board of Directors to resolve on a new issue, amendments to the articles of association and reduction of the share capital. Notice to convene the Extraordinary General Meeting will be announced in a separate press release. In total, the Rights Issue is covered by subscription commitments and guarantee commitments of up to approximately SEK 32 million, corresponding to approximately 60 percent of the Rights Issue.</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Summary</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>The Board of Directors of the Company today announces its intention to resolve on the Rights Issue provided that the shareholders at the Extraordinary General Meeting authorizes the Board of Directors to resolve on a new issue, resolves to amend the articles of association and reduction of the share capital. Notice to convene the Extraordinary General Meeting will be announced in a separate press release.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Upon full subscription, the Rights Issue will initially provide the Company with approximately SEK 53 million before transaction costs. The net proceeds from the Rights Issue are primarily intended to be used to complete Phase I (Ia and Ib), support business development activities, strengthen shared R&amp;D and manufacturing capabilities, investment in internal development, CMC-compatibility, grow the contract research business, increase service revenues and margins and co-finance grant projects.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>The subscription price for each unit in the Rights Issue will correspond to a TERP discount of at least 35 percent on the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the period commencing on 24 March 2026 and ending on 6 April 2026, however not exceeding SEK 5 and not lower than the new quota value of the Company’s share subject to resolution by the Extraordinary General Meeting (i.e. SEK 1.6). The warrants of series TO 13 are intended to be issued free of charge. The Board of Directors’ resolution and the final terms of the Rights Issue, including the subscription price, are expected to be announced no later than on or around 6 April 2026.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>The subscription period for the Rights Issue is expected to run from and including 16 April 2026, to and including 30 April 2026. The last day of trading in the Company’s shares with the right to receive subscription rights is expected to be 10 April 2026.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>In total, the Rights Issue is covered by subscription commitments and guarantee commitments of up to approximately SEK 32 million, corresponding to approximately 60 percent of the Rights Issue.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>One (1) warrant of series TO 13 is intended to entitle the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to 70 per cent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market between 20 August – 2 September 2026, however not lower than the quota value of the Company’s share (i.e. SEK 1.6 following the Extraordinary General Meeting). The exercise period for the warrants of series TO 13 is expected to occur between 7 – 21 September 2026.</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Full terms and conditions and instructions for the Rights Issue, as well as other information about the Company and information about commitments, will be presented in the prospectus that the Company is expected to publish prior to the commencement of the subscription period in the Rights Issue. The prospectus will be held available on ExpreS2ion’s website (www.expres2ionbio.com).</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>CEO Bent U. Frandsen comments:</span></strong></p><p class=\"\"><span>“The encouraging early immunogenicity observations from the ongoing Phase I trial of ES2B-C001 strengthen our confidence in both the program and the ExpreS2 platform. While the data remain preliminary, they support continued execution of the clinical plan as we advance toward key safety and dose-escalation milestones and prepare for additional clinical readouts as the study progresses.</span></p><p class=\"\"><span>Against this clinical backdrop, we believe it is the right time to ensure that the Company is appropriately funded for the next phase of execution. Following a comprehensive review of available strategic and financing alternatives, the Board has determined that the Rights Issue best supports the Company’s objectives. The Rights Issue is intended to ensure that we can progress ES2B-C001 through this important phase and to continue building the capabilities and partnerships that underpin our broader platform, pipeline, and service business. We believe this positions ExpreS2ion to advance multiple value drivers while maintaining a disciplined and capital-efficient approach.”</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Background and rationale</span></strong></p><p class=\"\"><span>ExpreS2ion is a biotechnology company focused on the development and application of advanced protein expression technologies for vaccines and immunotherapies targeting infectious diseases and cancer. The Company was founded on the recognition that the increasing structural complexity of modern biological drug candidates requires protein expression systems capable of producing high-quality, difficult-to-express proteins at scale. To address this need, ExpreS2ion has developed the ExpreS2 recombinant protein expression platform, which is designed to support all stages of vaccine and biologics discovery and research and development, as well as Good Manufacturing Practice manufacturing for clinical studies. The platform has been applied in multiple therapeutic areas and has been used in the production of antigens evaluated in clinical trials, including late-stage studies conducted by collaboration partners.</span></p><p class=\"\"><span>The ExpreS2 platform is primarily used to support the Company’s internal and collaborative development activities. As of the date of this press release, ExpreS2ion’s development activities comprise vaccine candidates across four disease areas, including both internally led programs and projects developed in collaboration with academic and industrial partners, where ExpreS2ion’s role may range from antigen design and production to early clinical development support. In addition to its internal and collaborative development activities, ExpreS2ion licenses the ExpreS2 platform to research institutions and pharmaceutical companies. These licensees may independently, or in cooperation with ExpreS2ion, develop biopharmaceutical drugs and vaccines based on proteins produced using the platform. Such agreements may generate revenue through license fees, service income, and, in certain cases, future milestone payments and royalties.</span></p><p class=\"\"><span>ExpreS2ion’s lead clinical program is ES2B-C001, a therapeutic cancer vaccine aimed at cancers overexpressing the HER2 receptor. A clinical phase I trial in metastatic breast cancer has started in three clinical sites in Austria. On February 3rd, 2026, ExpreS2ion announced that five out of six evaluable patients demonstrated a drug-specific immune response following treatment with ES2B-C001. The Company also reported that patient enrolment and screening continue to progress as planned, and that additional patients are available to proceed once dosing is permitted following the required safety reviews. Based on current visibility, ExpreS2ion remains on track to complete the dose-escalation portion of the study around mid-2026 and the expansion portion toward the end of 2026, subject to ongoing recruitment, safety reviews, and overall study conduct progressing as expected.</span></p><p class=\"\"><span>ES2B-C001 is an investigational immunotherapy product candidate that combines ExpreS2ion’s proprietary ExpreS2™ expression platform with a patented virus-like particle (VLP) technology to create a VLP-based vaccine construct targeting the HER2 receptor, a clinically validated cancer antigen. The VLP platform is in-licensed from AdaptVac (of which ExpreS2ion owns 34%).</span></p><p class=\"\"><span>Several approved therapies, including monoclonal antibodies such as Herceptin™ (trastuzumab) and Perjeta™ (pertuzumab), as well as antibody–drug conjugates (ADCs) such as Enhertu™ (trastuzumab deruxtecan) and Kadcyla™ (trastuzumab emtansine), also target the HER2 receptor. These antibody-based therapies require repeated administration and may be associated with treatment-related adverse events. In the metastatic setting, disease progression due to primary or acquired resistance to HER2-targeted therapies remains a clinical challenge. Accordingly, there continues to be medical interest in therapeutic approaches that may broaden or extend anti-HER2 immune responses.</span></p><p class=\"\"><span>Whereas currently approved monoclonal antibodies bind defined and limited epitopes within the extracellular portion of HER2, ES2B-C001 is designed to present the extracellular domain of HER2 in a VLP format. This design is intended to induce a polyclonal antibody response against multiple epitopes and may also stimulate cellular immune responses. VLP-based vaccines have demonstrated the ability, in other disease settings, to induce both humoral and cellular immune responses, including the potential for immunological memory.</span></p><p class=\"\"><span>ES2B-C001 is being developed as a novel active immunotherapy approach and may have the potential to be evaluated either as monotherapy or in combination with existing HER2-targeted treatments. The clinical safety, efficacy, dosing regimen, and potential advantages relative to existing therapies will need to be established in controlled clinical trials.</span></p><p class=\"\"><span>The ExpreS2™ platform has previously been used in the development of a VLP-based COVID-19 vaccine candidate evaluated in a Phase III clinical trial involving approximately 4,000 subjects. In addition, multiple pharmaceutical companies, including Merck and GSK, are developing or commercializing VLP-based technologies in oncology and infectious disease, reflecting broader industry interest in this modality.</span></p><p class=\"\"><span>It is estimated that 1 in 8 women will develop breast cancer in their lifetime. The company predicts that a novel HER-2 targeting treatment paradigm demonstrating benefits similar to those observed in preclinical investigations has the potential to achieve annual sales exceeding 5 billion USD.</span></p><p class=\"\"><span>The Company’s Board of Directors believes that the existing working capital is insufficient to meet its current needs for the next 12-month period. The Board of Directors therefore intends to resolve to carry out the Rights Issue in order to strengthen the Company's financial position and to be able to implement the Company's business plan and strategy, including activities for the coming year.</span></p><p class=\"\"><span>If the Rights Issue is fully subscribed the Company will receive approximately SEK 53 million which is intended to be used as follows (in the following order of priority, at the approximate amounts stated in brackets):</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><strong class=\"root-Tkn6WL2y\"><span>Advance ES2B-C001</span></strong><span>Complete Phase I (Ia and Ib) through safety and maximum tolerated dose readout, with potential immunogenicity and early efficacy signals, representing a key value inflection point, and support business development activities to pursue partnering or outlicensing opportunities (approx. 55%).</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><strong class=\"root-Tkn6WL2y\"><span>Strengthen shared R&amp;D and manufacturing capabilities</span></strong><span>Investment in internal development, CMC-compatibility, and platform capabilities that de-risk execution, improve manufacturability, and compound across programs (approximately 20%).</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><strong class=\"root-Tkn6WL2y\"><span>Grow the contract research business</span></strong><span>Increase service revenues and margins, and validate the platform with external customers (approx. 20%).</span></li></ul><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><strong class=\"root-Tkn6WL2y\"><span>Co-finance grant projects</span></strong><span>Limited co-financing of externally funded projects with future pipeline/licensing opportunities (approx. 5%).</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Rights Issue</span></strong></p><p class=\"\"><span>Provided that the shareholders at the Extraordinary General Meeting authorizes the Board of Directors of the Company to resolve on a new issue and resolve on amendments to the Articles of Association and reduction of the share capital, the Board of Directors of the Company is expected to resolve on the Rights Issue on or around 6 April 2026. The subscription period in the Rights Issue is expected to run from and including 16 April 2026, to and including 30 April 2026, and, if fully subscribed, will initially raise approximately SEK 53 million for the Company before transaction costs. The subscription price for each unit in the Rights Issue will correspond to a TERP discount of at least 35 percent on the volume-weighted average price on Nasdaq First North Growth Market during the period commencing on 24 March 2026 and ending on 6 April 2026, however not exceeding SEK 5 and not lower than the new quota value of the Company’s share subject to resolution by the Extraordinary General Meeting (i.e. SEK 1.6). The warrants of series TO 13 are intended to be issued free of charge.</span></p><p class=\"\"><span>One (1) warrant of series TO 13 is intended to entitle the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to 70 per cent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market between 20 August – 2 September 2026, however not lower than quota value of the Company’s share. The exercise period for the warrants of series TO 13 is expected to occur between 7 – 21 September 2026.</span></p><p class=\"\"><span>The Board’s decision and the final terms of the Rights Issue, including the subscription price, are expected to be announced no later than on or around 6 April 2026. For further information on the preliminary timetable, please refer to the section “Preliminary timetable” below.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Subscription commitments and guarantee commitments</span></strong></p><p class=\"\"><span>The Company has received subscription commitments from members of the Company’s Board of Directors and management, including CEO Bent U. Frandsen, totalling approximately SEK 1 million, corresponding to approximately 1 percent of the Rights Issue. No compensation will be paid for entered commitments.</span></p><p class=\"\"><span>The Company has also entered into agreements with a number of external investors regarding guarantee commitments totalling approximately SEK 31 million, corresponding to approximately 59 percent of the Rights Issue. According to the guarantee agreements, cash compensation of 14 percent of the guaranteed amount will be paid, corresponding to a total of approximately SEK 4 MSEK, or 14 percent of the guaranteed amount in the form of newly issued units in the Company, with the same terms and conditions as units in the Rights Issue, including the subscription price in the Rights Issue.</span></p><p class=\"\"><span>In total, the Rights Issue is covered by subscription commitments and guarantee commitments of up to approximately SEK 32 million, corresponding to approximately 60 percent of the Rights Issue. Neither the subscription commitments nor guarantee commitments are secured by bank guarantees, blocked funds, pledges or similar arrangements.</span></p><p class=\"\"><span>In order to enable the issue of shares as guarantee compensation to the guarantors who choose to receive guarantee compensation in the form of newly issued units, the Board of Directors has proposed that the Extraordinary General Meeting, also resolve to authorize the Board of Directors to resolve on the issue of such units to the guarantors.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Preliminary timetable for the Rights Issue</span></strong></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td colspan=\"1\" rowspan=\"1\"><span>1 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Extraordinary general meeting to resolve on authorisation for the Company’s Board of Directors, amendments to the articles of association and reduction of share capital</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>6 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Board of Directors’ resolution on the Rights Issue and announcement of final terms for the Rights Issue</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>10 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Last day of trading in the share including preferential rights</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>13 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>First day of trading in the share excluding preferential rights</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>13 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Estimated date for publication of the prospectus</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>14 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Record date for the Rights Issue</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>16 April 2026 – 27 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Trading in unit rights</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>16 April 2026 – 30 April 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Subscription period</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>4 May 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Estimated date for announcement of the outcome of the Rights Issue</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>16 April 2026 – 20 May 2026</span></td><td colspan=\"1\" rowspan=\"1\"><span>Trading in paid subscribed units (“</span><strong class=\"root-Tkn6WL2y\"><span>BTU</span></strong><span>”)</span></td></tr></tbody></table></div><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Lock-up undertakings</span></strong></p><p class=\"\"><span>Shareholding members of the Company’s Board of Directors and management have, subject to certain exceptions, undertaken not to sell shares or other financial instruments in the Company up until the date falling 90 calendar days after the announcement of the outcome of the Rights Issue.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Extraordinary general meeting</span></strong></p><p class=\"\"><span>The Board of Directors’ intention to resolve on the Rights Issue is conditional upon the shareholders at the Extraordinary General Meeting, authorizing the Board of Directors to resolve on a new issue and resolving to amend the Articles of Association and reduction of the share capital in accordance with the Board of Directors’ proposal to the Extraordinary General Meeting. Notice of the Extraordinary General Meeting will be announced in a separate press release.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Prospectus</span></strong></p><p class=\"\"><span>Full terms and conditions and instructions for the Rights Issue, as well as other information about the Company and information about commitments, will be presented in the prospectus that the Company is expected to publish on or around 13 April 2026. The prospectus will be held available on ExpreS2ion’s website (www.expres2ionbio.com).</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Advisors</span></strong></p><p class=\"\"><span>Schmidt Capital Advisors and Vator Securities are acting as financial advisors to the Company and BAHR is acting as legal advisor to the Company in connection with the Rights Issue.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Certified Adviser</span></strong></p><p class=\"\"><span>Redeye Sweden AB</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>For further information about ExpreS2ion, please contact:</span></strong></p><p class=\"\"><span>Bent U. Frandsen, CEO</span></p><p class=\"\"><span>Keith Alexander, CFO</span></p><p class=\"\"><span>Telephone: +45 2222 1019</span></p><p class=\"\"><span>E-mail:</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>About ExpreS2ion</span></strong></p><p class=\"\"><span>ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visitwww.expres2ionbio.com.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Important information</span></strong></p><p class=\"\"><span>The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in ExpreS2ion in any jurisdiction, neither from ExpreS2ion nor from someone else.</span></p><p class=\"\"><span>This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Vator Securities is acting for ExpreS2ion in connection with the Rights Issue and no one else and will not be responsible to anyone other than ExpreS2ion for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein.</span></p><p class=\"\"><span>This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.</span></p><p class=\"\"><span>This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU follow on prospectus regarding the Rights Issue described in this press release will be prepared and published by the Company. The prospectus will be scrutinized and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) being the national competent authority and be published and available on the Company's website thereafter.</span></p><p class=\"\"><span>In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Forward-looking statements</span></strong></p><p class=\"\"><span>This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as \"believe\", \"expect\", \"anticipate\", \"intend\", \"may\", \"plan\", \"estimate\", \"will\", \"should\", \"could\", \"aim\" or \"might\", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Growth Market rule book for issuers.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Information to distributors</span></strong></p><p class=\"\"><span>Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in ExpreS2ion have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in ExpreS2ion may decline and investors could lose all or part of their investment; the shares in ExpreS2ion offer no guaranteed income and no capital protection; and an investment in the shares in ExpreS2ion is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.</span></p><p class=\"\"><span>For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in ExpreS2ion.</span></p><p class=\"\"><span>Each distributor is responsible for undertaking its own target market assessment in respect of the shares in ExpreS2ion and determining appropriate distribution channels.</span></p><p class=\"\"><em><span>This information is information that ExpreS2ion Biotech Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-27 18:53 CET.</span></em></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Attachments</span></strong></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://storage.mfn.se/4af1e26d-b406-401b-ac08-fdbf160920fe/expres2ion-announces-the-board-of-directors-intention-to-resolve-on-a-rights-issue-of-units-of-approximately-sek-53-million.pdf\" rel=\"nofollow\" target=\"_blank\">EXPRES2ION ANNOUNCES THE BOARD OF DIRECTORS’ INTENTION TO RESOLVE ON A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 53 MILLION</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/modular_finance:5e9de14dab172:0-expres2ion-announces-the-board-of-directors-intention-to-resolve-on-a-rights-issue-of-units-of-approximately-sek-53-million/",
            "pub_date": "2026-02-28 01:53:00",
            "source": "MFN by Modular Finance",
            "kind": 1,
            "language": "en"
        }
    ]
}